ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Acquired by Calamos Advisors LLC

Calamos Advisors LLC raised its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 122.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 250,185 shares of the biotechnology company's stock after acquiring an additional 137,749 shares during the quarter. Calamos Advisors LLC owned about 0.11% of ADMA Biologics worth $1,131,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in ADMA. Federated Hermes Inc. lifted its stake in ADMA Biologics by 4.4% in the 4th quarter. Federated Hermes Inc. now owns 807,012 shares of the biotechnology company's stock worth $3,648,000 after purchasing an additional 33,767 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in ADMA Biologics by 20.8% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 56,706 shares of the biotechnology company's stock worth $256,000 after buying an additional 9,767 shares in the last quarter. Peregrine Capital Management LLC bought a new position in ADMA Biologics in the 4th quarter worth about $3,991,000. DekaBank Deutsche Girozentrale boosted its position in shares of ADMA Biologics by 1,359.9% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 236,178 shares of the biotechnology company's stock valued at $1,068,000 after acquiring an additional 220,000 shares during the last quarter. Finally, Arizona State Retirement System boosted its position in shares of ADMA Biologics by 4.9% during the 4th quarter. Arizona State Retirement System now owns 59,728 shares of the biotechnology company's stock valued at $270,000 after acquiring an additional 2,769 shares during the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Mizuho raised their target price on shares of ADMA Biologics from $9.00 to $10.00 and gave the company a "buy" rating in a research note on Friday, March 1st. Cantor Fitzgerald lifted their price objective on shares of ADMA Biologics from $6.50 to $8.00 and gave the stock an "overweight" rating in a report on Thursday, February 29th. Finally, HC Wainwright reissued a "buy" rating and issued a $7.50 target price (up previously from $6.00) on shares of ADMA Biologics in a research note on Tuesday, March 26th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $7.88.

ADMA Biologics Trading Down 1.1 %

Shares of ADMA stock traded down $0.07 on Monday, hitting $6.20. 2,299,015 shares of the company's stock traded hands, compared to its average volume of 2,655,006. ADMA Biologics, Inc. has a one year low of $3.06 and a one year high of $6.76. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.69 and a current ratio of 5.16. The company's fifty day simple moving average is $5.96 and its 200 day simple moving average is $4.78. The stock has a market capitalization of $1.41 billion, a price-to-earnings ratio of -48.23 and a beta of 0.46.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.02. ADMA Biologics had a positive return on equity of 0.49% and a negative net margin of 10.94%. The business had revenue of $73.90 million for the quarter, compared to analyst estimates of $73.50 million. Equities analysts forecast that ADMA Biologics, Inc. will post 0.3 EPS for the current year.

Insider Buying and Selling

In other news, Director Steve Elms sold 183,008 shares of ADMA Biologics stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $6.01, for a total value of $1,099,878.08. Following the sale, the director now directly owns 2,577,387 shares in the company, valued at approximately $15,490,095.87. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders have sold a total of 639,895 shares of company stock valued at $3,927,169 over the last three months. 5.90% of the stock is owned by company insiders.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.